Predictive biomarkers are becoming increasingly important tools in drug development and
clinical research. The importance of using both guidelines for specimen acquisition and …

Solid cancers are a leading cause of death worldwide, primarily due to the failure of effective
clinical detection and treatment of metastatic disease in distant sites. There is growing …

Background We evaluated discordance in expression measurements for estrogen receptor
(ER), progesterone receptor (PR), and HER2 between primary and recurrent tumors in …

The purpose of this work was to determine whether there are differences in PIK3CA mutation
status and PTEN protein expression between primary and matched metastatic breast tumors …

Background The humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin®) is a
new treatment modality for metastatic breast cancer, the efficacy of which is directly …

HER-2 overexpression, a predictive marker of tumour aggressiveness and responsiveness
to therapy, occurs in 20–30% of breast cancer. Although breast cancer is a heterogeneous …

Abstract Knowledge of HER2 status is a prerequisite when considering a patient's eligibility
for Herceptin (trastuzumab) therapy. Accurate assessment of HER2 status is essential to …

Discordance in estrogen (ER), progesterone (PR), and HER2/neu status between primary
breast tumours and metastatic disease is well recognized. In this review, we highlight how …

In this prospective study, we determined HER‐2 status in primary breast invasive
carcinomas and in the paired lymph node metastases (synchronous and metachronous) …

BACKGROUND Accurate assessment of HER‐2 status is necessary prior to anti‐HER‐2
antibody (trastuzumab) therapy for metastatic breast carcinoma. However, controversy exists …